Skip Nav Destination
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation
Issue Archive
December 18 2014
In this Issue
Table of Contents
INSIDE BLOOD COMMENTARIES
PERSPECTIVES
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Clinical Trials & Observations
Peter Dreger,Johannes Schetelig,Niels Andersen,Paolo Corradini,Michel van Gelder,John Gribben,Eva Kimby,Mauricette Michallet,Carol Moreno,Stephan Stilgenbauer,Emili Montserrat,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
EVIDENCE-BASED FOCUSED REVIEW
HOW I TREAT
How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach
Clinical Trials & Observations
CLINICAL TRIALS AND OBSERVATIONS
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Clinical Trials & Observations
Dieter Hoelzer,Jan Walewski,Hartmut Döhner,Andreas Viardot,Wolfgang Hiddemann,Karsten Spiekermann,Hubert Serve,Ulrich Dührsen,Andreas Hüttmann,Eckhard Thiel,Jolanta Dengler,Michael Kneba,Markus Schaich,Ingo G. H. Schmidt-Wolf,Joachim Beck,Bernd Hertenstein,Albrecht Reichle,Katarzyna Domanska-Czyz,Rainer Fietkau,Heinz-August Horst,Harald Rieder,Stefan Schwartz,Thomas Burmeister,Nicola Gökbuget,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Clinical Trials & Observations
Peter W. Collins,Guy Young,Karin Knobe,Faraizah Abdul Karim,Pantep Angchaisuksiri,Claus Banner,Türkiz Gürsel,Johnny Mahlangu,Tadashi Matsushita,Eveline P. Mauser-Bunschoten,Johannes Oldenburg,Christopher E. Walsh,Claude Negrier,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators,for the paradigm 2 Investigators
HEMATOPOIESIS AND STEM CELLS
Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice
Elise Peterson Lu,Michael McLellan,Li Ding,Robert Fulton,Elaine R. Mardis,Richard K. Wilson,Christopher A. Miller,Peter Westervelt,John F. DiPersio,Daniel C. Link,Matthew J. Walter,Timothy J. Ley,Timothy A. Graubert
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Both mature KIR+ and immature KIR− NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice
Ayline Kübler,Jeanette Woiterski,Kai-Erik Witte,Hans-Jörg Bühring,Udo F. Hartwig,Martin Ebinger,Lena Oevermann,Markus Mezger,Wolfgang Herr,Peter Lang,Rupert Handgretinger,Christian Münz,Maya C. André
MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons
Jiajia Pan,Larissa Lordier,Deborah Meyran,Philippe Rameau,Yann Lecluse,Susan Kitchen-Goosen,Idinath Badirou,Hayat Mokrani,Shuh Narumiya,Arthur S. Alberts,William Vainchenker,Yunhua Chang
RED CELLS, IRON, AND ERYTHROPOIESIS
Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation
Brief Report
Hao Xu,Nancy J. Wandersee,YiHe Guo,Deron W. Jones,Sandra L. Holzhauer,Madelyn S. Hanson,Evans Machogu,David C. Brousseau,Neil Hogg,John C. Densmore,Sushma Kaul,Cheryl A. Hillery,Kirkwood A. Pritchard, Jr
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation
Effie W. Petersdorf,Theodore A. Gooley,Mari Malkki,Andrea P. Bacigalupo,Anne Cesbron,Ernette Du Toit,Gerhard Ehninger,Torstein Egeland,Gottfried F. Fischer,Thibaut Gervais,Michael D. Haagenson,Mary M. Horowitz,Katharine Hsu,Pavel Jindra,Alejandro Madrigal,Machteld Oudshoorn,Olle Ringdén,Marlis L. Schroeder,Stephen R. Spellman,Jean-Marie Tiercy,Andrea Velardi,Campbell S. Witt,Colm O’Huigin,Richard Apps,Mary Carrington,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
![issue cover]()
Tubulin polymerization assays showed that myosin II inhibition by blebbistatin (25 μM) disturbed stress fiber formation but increased tubulin polymerization in CD41+ megakaryocytes (MKs). MKs were stained for tubulin (α and β [green]) and phalloidin-TRITC (red); DNA was stained with TOTO (blue). See the article by Pan et al on page 3967.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
